<DOC>
	<DOCNO>NCT02176239</DOCNO>
	<brief_summary>The purpose study demonstrate utility measure outcomes 5 % treatment naïve Intravenous Immunoglobulin ( IVIg ) Primary Immunodeficiency Disease ( PIDD ) patient use infusion nurse patient measure physical , quality life ( QOL ) , respiratory , disability assessment use CareExchange home setting .</brief_summary>
	<brief_title>Monitoring 5 % Treatment Naïve Intravenous Immunoglobulin ( IVIg ) Primary Immunodeficiency Disease ( PIDD ) Patients Using CareExchange® System : A Pilot Study Using 5 % Gammaplex® IVIg Home Setting</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Diagnosis form Primary Immunodeficiency Disease Males Females ≥ 15 ≤ 85 year age 5 % treatment Naïve IVIg treatment PIDD Ability Gammaplex® IVIg prescribe discretion patient 's treat physician accordance standard treatment practice entire duration study Ability willingness provide inform consent comply study requirement procedures Ability read write English Understanding study procedure ability comply study procedure entire length study Eligible infusion service AxelaCare Health Solutions , LLC , collaboration subject 's prescribing physician insurance provider The presence medical condition investigator and/or prescribe physician deems incompatible participation trial . Prisoners , ward state Determined noncompetency data collection requirement ( physical assessment use iPAD™ ) either home infusion nurse and/or Caregiver . Receiving Subcutaneous Immunoglobulin ( SCIg ) Therapy study participation .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>